Table 1.

Patient characteristics for each donor type

CB (n = 1915)MRD (n = 1772)1-MMRD (n = 225)MUD (n = 1742)1-MMUD (n = 963)P
Age at HSCT, median (range), y44 (0-85)40 (0-74)32 (0-68)45 (0-72)44 (0-71)
 0-20419 (21.9)294 (16.6)75 (33.3)213 (12.2)149 (15.5)<.01
 21-40415 (21.7)618 (34.9)66 (29.3)470 (27.0)258 (26.8)
 41-60667 (34.8)707 (39.9)62 (27.6)754 (43.3)435 (45.1)
 ≥61414 (21.6)153 (8.6)22 (9.8)305 (17.5)121 (12.6)
Year of HSCT
 2008-2011734 (38.3)848 (47.9)112 (49.8)707 (40.6)373 (38.7)<.01
 2012-20151181 (61.7)924 (52.1)113 (50.2)1035 (59.4)590 (61.3)
Patient sex
 Male1037 (54.2)1005 (56.7)140 (62.2)984 (56.5)540 (56.1).03
 Female878 (45.8)767 (43.3)85 (37.8)758 (43.5)423 (43.9)
Disease
 ALL761 (39.7)734 (41.4)93 (41.3)681 (39.1)393 (40.8).66
 AML1154 (60.3)1038 (58.6)132 (58.7)1061 (60.9)570 (59.2)
Disease status at HSCT
 CR11375 (72.2)1427 (80.7)153 (68.0)1347 (77.5)692 (71.9).01
 ≥CR2530 (27.8)342 (19.3)72 (32.0)392 (22.5)271 (28.1)
 Unknown10 (0.5)3 (0.2)0 (0.0)3 (0.2)0 (0.0)<.01
ECOG-PS
 0-21801 (94.0)1711 (96.6)211 (93.8)1678 (96.3)917 (95.2)<.01
 3-4104 (5.5)57 (3.2)14 (6.2)60 (3.5)46 (4.8)
 Unknown10 (0.5)4 (0.2)0 (0.0)4 (0.2)0 (0.0)
Donor source
 BM808 (45.6)110 (48.9)1699 (97.5)961 (99.8)<.01
 PB964 (54.4)115 (51.1)43 (2.5)2 (0.2)
HLA disparity
 Match251 (13.1)17721742
 Mismatch1664 (86.9)225963
Conditioning regimen
 Myeloablative1111 (58.0)1326 (74.8)149 (66.2)1145 (65.7)640 (66.5)<.01
 BU/TBI based188/923302/102441/108263/882131/509
 Reduced intensity801 (41.8)445 (25.1)76 (33.8)594 (34.1)323 (33.5)
 Unknown3 (0.2)1 (0.1)0 (0.0)3 (0.2)0 (0.0)
GVHD prophylaxis
 Tac based1347 (70.3)330 (18.6)187 (83.1)1484 (85.2)868 (90.2)<.01
 CyA based553 (28.9)1405 (79.3)34 (15.1)236 (13.6)83 (8.6)
 Others/unknown15 (0.8)37 (2.1)4 (1.8)22 (1.2)12 (1.2)
Use of ATG
 ATG(−)1862 (97.2)1754 (99.0)153 (68.0)1709 (98.1)860 (89.3)<.01
 ATG(+)53 (2.8)18 (1.0)72 (32.0)33 (1.9)103 (10.7)
  • Data are presented as n (%), unless otherwise indicated.

  • —, not applicable; BU, busulfan; CyA, cyclosporin A; TBI, total body irradiation; Tac, tacrolimus.